Last updated: 2026-09-16 09:04:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Omeros Corporation (OMER) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $17.06, with a market capitalisation of $1.26B and a P/E ratio of 9.96. Over the past 52 weeks, its price has ranged from $3.94 to $19.65. This page covers its latest market performance, valuation, price trends and company information.
$1.26B | |
$17.06 | |
$30.23 | |
$0.92 | |
$17.17 | |
47.00 | |
1.95M | |
9.96 | |
$19.65 | |
$3.94 | |
-- | |
-- |
Omeros Corporation (OMER) is trading at $17.06 in pre-market trading as of 2026-09-16 08:01:00, down 0.67% ($0.12) from the previous close of $17.17
Pre-market trading shows how investors are pricing OMER before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Omeros Corporation (OMER) moved from $18.95 to $17.06, representing a decline of 10.00% ($1.89).
The stock traded between $16.50 and $19.55 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.29 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 83.5%
OMER is currently trading at $17.06, placing it 83.5% of the way from its 52-week low of $3.94 to its 52-week high of $19.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 175 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Omeros Corporation (OMER) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.